Sunil Badve

Excited to share our latest study showing kidney, CV and survival benefits of GLP-1 receptor agonists just published in @TheLancetEndo Time-limited free access authors.elsevier.com/a/1k9u77tNucqx… 1/

@eric_weinhandl Considering the short follow up of the trial, the effect size is actually quite impressive.

Press release about atrasentan in IgA nephropathy (ALIGN trial). Very small effect size. novartis.com/news/media-rel…

Dr. Mike Sharma and I discuss the results of the phase III OCEANIC-STROKE Trial: In secondary stroke prevention the Factor Xi inhibitor Asundexian reduced the risk of recurrent ischemic stroke at 1 year by 26%. The absolute reduction was such that only 53 people would we need to be treated to prevent another stroke at 1 year. There was no increase in mild or severe bleeding or intracranial bleeding 63% of people were on DAPT at study start, and they had the same benefit as people on antiplatelet monotherapy Similar benefit in medium to large vessel ischemic stroke, lacunar stroke and stroke of unidentified origin All benefit with no increase in bleeding risk View slides here: clinicaltrialresults.org/dr-mike-sharma…

I’m not surprised the manuscript was accepted. It’s so believable!

Scientists found a way to reverse kidney damage—is a cure next? - National Geographic It's about the 4-pillar approach to CKD with Kathleen Tuttle, Vlado Perkovic, and Prabir Roy-Chaudhury, among others apple.news/AdOdbxi3GRMWOI…

@SabeloShezi_ Cystatin C is normal. He does not have CKD Cr in the blood reflects production (muscle mass dependent) & GFR. Think of cystatin C as a muscle mass ignorant Cr level. Most creatine OTC formulations do not increase Cr contrary to popular belief, Kid Int (2019) 96, 527–528

KDIGO is pleased to share the newly published report from its Controversies Conference on Preventing CKD and Maintaining Kidney Health, now available in press in @Kidney_Int. 📄Download the report: kdigo.co/2025-CKD-Preve… 📘 Read the report in KI: kdigo.co/KDIGO-2025-CKD… Co-chaired by Dr. Alberto Ortiz and Dr. Kathy Tuttle, the conference brought together global experts and patient advocates to reframe how kidney disease is addressed, prioritizing prevention, early detection, and long-term kidney health across the lifespan. “CKD affects over 800 million people worldwide and is one of the major unsolved challenges in global health,” said Dr. Ortiz. “We need structural changes that support proactive primary prevention in addition to earlier diagnosis and treatment—especially in low- and middle-income countries.” “The data now show that kidney disease is not inevitable. In many cases, it can be delayed—or even prevented—if we intervene early," said Dr Tuttle. "We need to treat CKD prevention as a public health priority, like we’ve done for heart disease and diabetes. That means integrating kidney health into the entire continuum of chronic disease prevention and empowering both clinicians and patients through education and awareness.” #kidneyhealth #publichealth #CKD

IMJ June 2025 #FreeAccess Editorial: Smokers and kidney transplantation assessment: a question of risk or equity? bit.ly/3FUCH8Q @TheRACP @WileyHealth @Badves

IMJ June 2025 #OpenAccess Editor's choice (Original Article): Smoking and kidney transplantation wait listing bit.ly/4kFslsJ @TheRACP @WileyHealth @Badves

Save the date for Kidney Supportive Care Masterclass 2025 and Serious Illness Conversations Workshop. Open to nephrologists, nephrology trainees and nurse practitioners. Separate registrations for the Masterclass (forms.office.com/r/L90B6DrscS) and the Workshop (email in the image).

In SOUL, 2596/9650 (26.9%) participants were receiving SGLT2i at baseline (largest CVOT of combined GLP-1/SGLT2 to date) The effect of oral semaglutide on cardiovascular outcomes was consistent, regardless of SGLT2i use #ACC25 ahajournals.org/doi/abs/10.116…

Cardiovascular, Kidney & Mortality Outcomes With Injectable & Oral GLP1-RA in T2 Diabetes An updated meta-analysis of >70,000 patients after the SOUL trial by @matthewmylee et al. ⬇️ 14% MACE ⬇️ 14% heart failure ⬇️ 17% CKD ⬇️ 12% all-cause mortality diabetesjournals.org/care/article/d…

Evidence is thin that hypertension causes chronic kidney disease. academic.oup.com/ndt/advance-ar…

A randomized controlled trial evaluated the efficacy and safety of #apixaban for prevention of recurrent thrombosis after #thrombectomy of #hemodialysis #vascularaccess doi.org/10.1016/j.kint…

@LRSorce @SebastianPalmqv @NiklasMattsson4 @criticcaredoc @TobyMMaher @AlexSpyropoul Most Viewed JAMA 2024: Medications for Obesity 🔗 ja.ma/3Djs3ab @DrRobertKushner

Five fielders and the wicket keeper are wearing a helmet. Must be a record. #INDvsAUS

#ICYMI: GLP-1 RA with and without SGLT2i @mvaduganathan @Badves @RpratleyMD @lheath @brendonneuen

📢 #GLP1 receptor agonists improve both kidney- and heart-related clinical outcomes for individuals with: ▶️ #type2diabetes ▶️ #chronickidneydisease ▶️ #overweight and #obesity @Nephronline @CardiologyToday @TheLancetEndo @Badves @georgeinstitute healio.com/news/endocrino…

Clear reductions in all outcomes with GLP-1RA: Kidney failure ✅ Major CV events ✅ Heart failure ✅ CV death ✅ All-cause death ✅ Updated systematic review/meta-analysis of 11 trials ~85,000 participants, with & without diabetes Now in @TheLancetEndo thelancet.com/journals/landi…

New—Effects of #GLP-1 receptor agonists on #kidney and #cardiovascular disease outcomes: a meta-analysis of randomised controlled trials thelancet.com/journals/landi… #T2D #CVD

Popular diabetes drugs like Ozempic can reduce the risk of kidney failure and death due to kidney or cardiovascular causes in people with and without diabetes, new research from @Badves and @VladoPerkovic shows. @georgeinstitute bit.ly/3Zru4K4